文献速递肿瘤 PET/CT骨显像与常规 SPECT

转移性激素敏感性前列腺癌中的低瘤负荷与高瘤负荷疾病:从CHAARTED标准到PSMA PET——一项国际多中心回顾性研究

Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
PubMed 文献 · J Nucl Med · 2025-01-03

该国际多中心回顾性研究纳入67例转移性激素敏感性前列腺癌患者,比较基于传统影像(CT/MRI联合骨扫描)的CHAARTED高/低瘤负荷标准与基于PSMA PET的瘤负荷定义。结果显示,PSMA PET导致40.3%的患者发生分期迁移,其中每3例中约1例降期为M0,每5例中约1例从低瘤负荷升为高瘤负荷;基于全身PSMA PET阳性肿瘤体积区分传统影像低/高瘤负荷的最佳阈值为107 mL,误分类率21.9%。

要点

  • 传统影像定义高瘤负荷17/67例(25.4%),PSMA PET定义高瘤负荷27/67例(40.3%)。
  • PSMA PET使16/67例(22.4%)判为无可见病灶或仅盆腔区域性病变(M0)。
  • 27/67例(40.3%)发生分期迁移:11/50例低瘤负荷传统影像患者升为高瘤负荷PET。

核心结论

  • 与传统影像相比,加做PSMA PET可使每3例转移性激素敏感性前列腺癌患者中约1例降期为M0,每5例中约1例从低瘤负荷升为高瘤负荷。
  • 未来基于PSMA PET/CT的高瘤负荷与低瘤负荷定义应根据患者结局进行调整。

研究设计与样本

  • 回顾性多中心研究,纳入5个国际中心的转移性激素敏感性前列腺癌患者,PSMA PET/CT或PSMA PET/MRI与骨扫描间隔在100天内且两次扫描之间未开始新治疗。
  • 共纳入67例有配对PSMA PET和骨扫描的患者,中位前列腺特异性抗原水平为54.9 ng/mL(四分位距10.4-191.0 ng/mL)。
  • 将CHAARTED高瘤负荷与低瘤负荷标准应用于骨扫描、CT、MRI和PSMA PET;高瘤负荷定义为存在内脏转移或至少4处骨转移(其中至少1处位于脊柱或骨盆以外)。
  • 全身肿瘤负荷分别用骨扫描上的自动骨扫描指数(aBSI,EXINI v2.0)和PSMA PET上的全身PSMA PET阳性肿瘤体积(PSMA-TV)估算。

主要发现

  • 基于传统影像,17/67例(25.4%)为高瘤负荷,50/67例(74.6%)为低瘤负荷;基于PSMA PET,27/67例(40.3%)为高瘤负荷,24/67例(35.8%)为低瘤负荷,16/67例(22.4%)为无可见病灶或仅盆腔区域性病变(M0)。
  • 传统影像与PSMA PET之间分期迁移发生于27/67例(40.3%),包括升级和降级:11/50例(22%)传统影像低瘤负荷患者为PSMA PET高瘤负荷,1/17例(5.9%)传统影像高瘤负荷患者和15/50例(30%)传统影像低瘤负荷患者为PSMA PET M0。
  • 传统影像高瘤负荷组中位全身PSMA-TV为248.0 mL(四分位距54.6-1,427.0 mL),中位自动骨扫描指数为3.4%(四分位距1.0-7.2%);传统影像低瘤负荷组分别为25.1 mL(四分位距6.6-74.6 mL)和0.1%(四分位距0.0-0.2%)。
  • PSMA PET高瘤负荷组中位全身PSMA-TV为141.0 mL(四分位距47.5-458.0 mL),中位自动骨扫描指数为0.9%(四分位距0.04-4.1%);PSMA PET低瘤负荷组分别为31.5 mL(四分位距10.1-67.9 mL)和0%(四分位距0-0.1%)。
  • 区分传统影像CHAARTED低瘤负荷与高瘤负荷的最佳全身PSMA-TV阈值为107 mL,误分类率为21.9%。

关键数值与推荐

  • CHAARTED高瘤负荷定义:存在内脏转移或至少4处骨转移(其中至少1处位于脊柱或骨盆以外)。
  • 基于传统影像:高瘤负荷17/67例(25.4%),低瘤负荷50/67例(74.6%)。
  • 基于PSMA PET:高瘤负荷27/67例(40.3%),低瘤负荷24/67例(35.8%),M0 16/67例(22.4%)。
  • 区分传统影像低瘤负荷与高瘤负荷的最佳全身PSMA-TV阈值为107 mL,误分类率21.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria. HVD and LVD definitions are associated with overall survival and are used for treatment decisions. It remains unknown how these definitions transfer to prostate-specific membrane antigen (PSMA) PET imaging. The aim of this retrospective multicenter study was to compare the CI-based disease volume criteria to PSMA PET-based volume definitions in a CHAARTED-like cohort. Methods: mHSPC patients from 5 international sites who underwent PSMA PET/CT or PSMA PET/MRI and BS within a time interval of 100 d and without initiation of a new therapy between the 2 scans were retrospectively included in the analysis. CHAARTED HVD and LVD criteria were applied to BS, CT, MRI, and PSMA PET. HVD was defined by the presence of visceral metastases or at least 4 bone metastases (with ≥1 beyond the spine or pelvis). Whole-body (WB) tumor burden was estimated with the automated bone scan index (aBSI, EXINI v2.0) on BS and with the WB PSMA PET-positive tumor volume (PSMA-TV) on PSMA PET, respectively. Results: Sixty-seven patients with paired PSMA PET and BS were included. The median prostate-specific antigen level was 54.9 ng/mL (interquartile range [IQR], 10.4-191.0 ng/mL). On the basis of CI, it was determined that 17 of 67 patients had HVD-CI (25.4%) and 50 of 67 patients had LVD-CI (74.6%). On the basis of PSMA PET, it was determined that 27 of 67 patients had HVD-PET (40.3%) and 24 of 67 patients had LVD-PET (35.8%). In total, 16 of 67 patients (22.4%) had no visible lesion or only locoregional pelvic disease (M0) with PSMA PET (M0-PET). Stage migration between CI and PSMA PET occurred in 27 of 67 patients (40.3%) by both upstaging and downstaging: 11 of 50 (22%) LVD-CI patients were HVD-PET, whereas 1 of 17 (5.9%) HVD-CI and 15 of 50 (30%) of LVD-CI patients were M0-PET. The median WB PSMA-TV and automated BS index were 248.0 mL (IQR, 54.6-1,427.0 mL) and 3.4% (IQR, 1,0-7.2%) for HVD-CI, 25.1 mL (IQR, 6.6-74.6 mL) and 0.1% (IQR, 0.0-0.2%) for LVD-CI, 141.0 mL (IQR, 47.5-458.0 mL) and 0.9% (IQR, 0.04-4.1%) for HVD-PET, and 31.5 mL (IQR, 10.1-67.9 mL) and 0% (IQR, 0-0.1%) for LVD-PET, respectively. The optimal WB PSMA-TV to stratify CI-based CHAARTED LVD-CI versus HVD-CI was 107 mL with a misclassification of 21.9%. Conclusion: Compared with CI, addition of PSMA PET leads to M0 downstaging in every third and LVD to HVD upstaging in every fifth mHSPC patient. Future HVD and LVD definitions based on PSMA PET/CT should be adjusted based on patient outcome.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Unterrainer LM, Hope TA, Fendler WP, et al. Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025. PMID: 39753363. doi:10.2967/jnumed.124.268441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。